Program
MHB018A
A development code. Also written as “MHB018A injection”.
Its studies are mostly in Graves Ophthalmopathy, led by Minghui Pharmaceutical.
Furthest: phase 3, since May 9, 20256 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minghui Pharmaceutical | 66 open or running | phase 3since May 9, 2025 | May 9, 2025 | Dec 2026phase 3 · NCT06989918 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2025First study: phase 3 study in Graves OphthalmopathyFirst studyNCT06989918 · 108 enrolled · China
- Nov 20, 20252 phase 3 studies in Graves OphthalmopathyNCT07262476, NCT07257185
- May 27, 20263 phase 3 studies in Graves OphthalmopathyNCT07622121, NCT07622108, NCT07620405
- Oct 9, 2026Primary completion moved from 2026-07-31 to 2026-12Date moved laterphase 3 · +5 months · NCT06989918
Ahead
- Dec 2026Primary completion: phase 3 study in Graves OphthalmopathyNCT06989918
- Aug 31, 2027Primary completion: phase 3 study in Graves OphthalmopathyNCT07257185
- Jul 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07622121
- Jul 2028Primary completion: phase 3 study in Graves OphthalmopathyNCT07622108
TargetBeta
IGF1R →read by rule
“The investigational drug, MHB018A, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).”study text, by rule · the study
Other programs on IGF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| teprotumumabrule | Amgen | phase 4 | 18 |
| veligrotugrule | viridian-therapeutics-inc | phase 4 | 7 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| IBI311rule | Innovent Biologics | phase 3 | 5 |
| IBI3031rule | Innovent Biologics | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07622121Graves Ophthalmopathy · United States | 3 | Recruiting | Jul 2028 | 135 |
| NCT07622108Graves Ophthalmopathy · United States | 3 | Recruiting | Jul 2028 | 84 |
| NCT07620405Graves Ophthalmopathy | 3 | Not yet recruiting | Jan 2030 | 219 |
| NCT07262476Graves Ophthalmopathy · China | 3 | Recruiting | Jan 31, 2029 | 258 |
| NCT07257185Graves Ophthalmopathy · China | 3 | Active, not recruiting | Aug 31, 2027 | 150 |
| NCT06989918Graves Ophthalmopathy · China | 3 | Active, not recruiting | Dec 2026 | 108 |
How it is read
Names in the registry
- “MHB018A injection”, 4 entries
- “MHB018A”, 2 entries
Codes read as this program: MHB018A.
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.